Expert.ai S.p.A. (EXAI)
4.840
0.00 (0.00%)
Inactive · Last trade price on Nov 19, 2024

Company Description

Expert.ai S.p.A., an artificial intelligence (AI) platform company, develops and sells cognitive computing software products based on AI algorithms to read and understand written language worldwide.

The company offers expert.ai Platform that captures the strategic value of language data; expert.ai Answers, a customer support automation software that allows human like interaction between customers and internal staff, using the language of business and users; expert.ai Discover, a text analytics, and extraction and categorization software; expert.ai for Insurance that automate insurance claims management with natural language understanding; and expert.ai for Life Sciences to mimic the human like comprehension of scientific content, such as publications, patents, clinical trials, or medical reports.

It serves the banking and insurance, public administration, life science and pharma, oil and gas, media and publishing, and telecom and utilities industries, as well as defense, and intelligence and law enforcement industries.

Expert.ai S.p.A. has a strategic partnership agreement with WealthIntel Inc. to facilitate innovations in natural language and text analytics.

The company was formerly known as Expert System S.p.A. and changed its name to Expert.ai S.p.A. in May 2021.

Expert.ai S.p.A. was founded in 1989 and is headquartered in Modena, Italy.

Expert.ai S.p.A.
Exscientia logo
Country Italy
Founded 1989
IPO Date Oct 1, 2021
Industry Biotechnology
Sector Healthcare
Employees 300
CEO David Hallett

Contact Details

Address:
Via Virgilio 56/Q
Modena, 41123
Italy
Phone 39 059 894011
Website expert.ai

Stock Details

Ticker Symbol EXAI
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency EUR
IPO Price $22.00
CIK Code 0001865408
CUSIP Number 30223G102
ISIN Number US30223G1022
SIC Code 7372

Key Executives

Name Position
Dr. David Hallett Ph.D. Chief Scientific Officer, Interim Chief Executive Officer, Principal Executive Officer and Executive Director
Ben R. Taylor Chief Financial Officer, Chief Strategy Officer and Executive Director
Dr. John P. Overington Ph.D. Chief Technology Officer
Sara Sherman Vice President of Investor Relations
Dan Ireland Executive Vice President of Legal and Company Secretary
Parker Moss Executive Vice President of Corporate Development
Caroline Rowland Chief People Officer
Richard Law Chief Business Officer
Nikolaus Krall Executive Vice President of Precision Medicine
Dr. Marie-Louise Helena Fjallskog M.D., Ph.D. Interim Chief Medical Officer and Clinical Development Lead

Latest SEC Filings

Date Type Title
Nov 20, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Nov 20, 2024 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Nov 20, 2024 6-K Report of foreign issuer
Nov 20, 2024 25-NSE Filing
Nov 13, 2024 6-K Report of foreign issuer
Nov 12, 2024 6-K Report of foreign issuer
Nov 8, 2024 6-K Report of foreign issuer
Nov 6, 2024 6-K Report of foreign issuer
Oct 24, 2024 144 Filing
Oct 10, 2024 6-K Report of foreign issuer